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ABSTRACT
Background Immune checkpoint blockade (ICB) response
in recurrent/metastatic head and neck squamous cell
carcinoma (HNSCC) is limited to 15%–20% of patients and
underpinnings of resistance remain undefined.
Methods Starting with an anti-PD1 sensitive murine
HNSCC cell line, we generated an isogenic anti-PD1
resistant model. Mass cytometry was used to delineate
tumor microenvironments of both sensitive parental
murine oral carcinoma (MOC1) and resistant MOC1esc1
tumors. To examine heterogeneity and clonal dynamics of
tumor infiltrating lymphocytes (TILs), we applied paired
single-cell RNA and TCR sequencing in three HNSCC
models.
Results Anti-PD1 resistant MOC1esc1 line displayed
a conserved cell intrinsic immune evasion signature.
Immunoprofiling showed distinct baseline tumor
microenvironments of MOC1 and MOC1esc1, as well
as the remodeling of immune compartments on ICB
in MOC1esc1 tumors. Single cell sequencing analysis
identified several CD8 +TIL subsets including Tcf7 +Pd1−
(naïve/memory-like), Tcf7 +Pd1+ (progenitor), and
Tcf7-Pd1+ (differentiated effector). Mapping TCR shared
fractions identified that successful anti-PD1 or anti-CTLA4
therapy-induced higher post-treatment T cell lineage
transitions.
Conclusions These data highlight critical aspects of
CD8 +TIL heterogeneity and differentiation and suggest
facilitation of CD8 +TIL differentiation as a strategy to
improve HNSCC ICB response.

INTRODUCTION
PD1 blockade with nivolumab or pembrolizumab has shown durable antitumor efficacy in recurrent/metastatic head and neck
squamous cell carcinoma (HNSCC) patients
although only 15%–20% of patients respond
to the therapy.1 2 Immune checkpoint
blockade (ICB) therapies aim to target the
interaction between coinhibitory ligands and
receptors, such as between PD-L1 and PD1, to
reinvigorate dysfunctional tumor infiltrating

T cells. Various factors have been reported to
impact the efficacy of ICB therapy, including
tumor mutation or neoantigen burden,3–5
cancer cell intrinsic factors,6 7 T cell infiltration,8 PD-
L1 expression,9 IFNγ signaling
pathway activity, antigen presentation,10–12
an immunosuppressive tumor microenvironment (TME),13 14 and gut microbiome
composition.15–17
However,
important
details about the cellular mechanism of ICB-
induced tumor rejection are still lacking. In
both chronic infection and various cancers,
T cell exhaustion induced by chronic TCR
signaling, as opposed to acute antigen clearance, represents a distinct transcriptional and
epigenetic state in T cell differentiation.18–20
Recent studies have begun to investigate the heterogeneity of antigen specific
CD8 +tumor infiltrating lymphocytes (TILs)
and how subpopulations contribute to ICB
treatment and tumor response. Mouse
models of chronic lymphocytic choriomeningitis virus (LCMV) and B16 melanoma
expressing SIINFEKL identified a unique
subset of Tcf7 +Pd1+ ‘progenitor’ cells as a
major CD8 +T cell subpopulation responsive
to anti-
PD1 therapy.21 22 As these findings
were all discovered from high affinity model
antigens, the implications for total CD8 +TIL
heterogeneity, T cell lineage dynamics, and
the differential response of T cell subsets
to anti-
PD1 or anti-
CTLA4 treatment are
unclear. These investigations are important
to our understanding of ICB mediated
responses in human tumors where a wide
range of natural antigens is present.
We previously developed novel syngeneic
murine oral carcinoma (MOC) models that
recapitulate cardinal features of human
HNSCC.23 24 In this study, using three murine
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METHODS
Cell lines and mice
Mouse oral squamous cell carcinoma models, MOC1,
MOC1esc1, and MOC22 were maintained as previously
described23 24 in IMDM/Hams-F12 (2:1) supplemented
with 5% heat inactivated FBS, 100 U/mL penicillin streptomycin, 5 ng/mL EGF (Millipore), 400 ng/mL hydrocortisone (Sigma Aldrich), and 5 µg/mL insulin (Sigma
Aldrich). Cell lines were routinely tested for mycoplasma every 6 months. Female wild type C57BL/6 mice
(Taconic Biosciences, 7–10 weeks age, acclimatized for
48 hours) and NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) were
housed in a pathogen-free animal facility. All experiments
performed were approved by the Dana-Farber Cancer
Institute IACUC.
Tumor implantation and in vivo antibody treatment
For tumor implantation, MOC cells were harvested
and washed extensively with cold endotoxin free PBS.
For scRNA-seq and mass cytometry experiments, 5*106
MOC1, MOC1esc1, or MOC22 cells were injected for each
tumor in a volume of 150 µL. Tumor cells were injected
subcutaneously into the flank of each mouse (sample size
based on historical data). For tumor growth monitoring,
106 cells were injected for each tumor. ICB therapy was
performed by IP injections of anti-
PD1 (250 µg per
mouse for each injection), and isotype control (250 µg
per mouse for each injection), or anti-CTLA4 (200 µg
per mouse for the first injection, and 100 µg per mouse
for the second and third injections) on days 3, 6, 9 post-
tumor implantations. For Treg depletion study, mice were
IP injected with 200 µg of anti-CD25 antibody every 7 days
beginning 1 day before tumor implantation. For tumor-
associated macrophages (TAM) depletion study, mice
were IP injected with 1 mg of anti-CSF1R antibody every
3 days beginning 1 day before tumor implantation. Additional information is in online supplemental methods.
Mass cytometry
CyTOF staining was performed as previously described.25
Cells were analyzed on a Helios mass cytometer (Fluidigm). Normalization and deconvolution of the single
pooled sample was conducted with the normalizer and
the single-
cell-
debarcoder software developed in the
2

Nolan Lab (Stanford). Data analysis was conducted using
Cytobank (Cytobank).
ScRNA-seq and TCR-seq
Note, details on additional genomic analysis are in
online supplemental methods. ScRNA-seq and TCR-seq
processing was completed using the 10× Chromium instrument (10× Genomics). The single-cell RNA-seq libraries
were processed using Chromium single-cell 5’ library and
gel bead kit and coupled TCR-seq libraries were obtained
using Chromium single-cell V(D)J enrichment kit (10×
Genomics). Quality control for amplified cDNA libraries
and final sequencing libraries were performed using
Bioanalyzer High Sensitivity DNA Kit (Agilent). Both
scRNA-seq and TCR-seq libraries were normalized to 4
nM concentration and pooled in a volume ratio of 4:1.
The pooled mouse libraries were sequenced on an Illumina NovaSeq S4 platform.
ScRNA-seq data were aligned to the MM10 reference
genome. The raw sequencing data were processed with
Cell Ranger V.3.0.2 software (https://www.10xgenomics.
com/) for initial quality control. Filtered gene-barcode
matrix files were further parsed with Seurat V.3.0.01 for
fine-grain quality control and downstream analyses.
Diffusion map and pseudotime analysis
Single-cell pseudotime trajectories were constructed by
diffusion maps using R package destiny.26 Naïve/memory
and exhaustion gene sets from the GSEA/mSigDB hallmark gene set collection38 (http://software.broadinstitute.org/gsea/msigdb/collections.jsp#H: M5834 and
M3012) were used as input gene matrix for the diffusion
map analysis. To visualize the T cell differentiation trajectory, we extracted the first component from the diffusion
map results, and the coefficients in this component were
presented.
Data processing of scTCR-seq libraries
TCR sequencing data were aligned to the MM10 reference
genome and RefSeq gene models using cellranger vdj
(https://www.10xgenomics.com/). TCR alpha and beta
chain sequences from individual cell were used to infer
clonotypes. The clonotype comparison feature in Loupe
Cell Browser (10× Genomics) was then used to pool TCR
clonotypes across groups by matching CDR3 amino acids
of both TCR alpha and beta chains . Clonotypes were
assigned a clonal expansion pattern based on their clone
sizes shared between cells in individual samples.
Statistical analysis
For in vitro and in vivo mouse model studies, data are
plotted as the mean±SD or mean±SEM. Statistical significance was determined by student’s t-test, one-way analysis
of variance (ANOVA) and two-way ANOVA (GraphPad
Prism). Significance differences p<0.05, 0.01, 0.001 were
symbolized as *, **, and ***, respectively. The statistical
methods used for bulk RNA-seq and single cell analysis
are described within the figure legend.
Zhou L, et al. J Immunother Cancer 2022;10:e004034. doi:10.1136/jitc-2021-004034
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HNSCC models that display distinct sensitivity or resistance phenotypes to anti-
PD1 or anti-
CTLA4 therapy,
we comprehensively characterized the TME, as well as
the T cell transcriptomic profile and lineage dynamics
using single-
cell mass cytometry (CyTOF), RNA-
seq
(scRNA-seq), and T cell receptor sequencing (scTCR-seq).
Together this study highlights that, globally, T cells are
distributed in distinct differentiation states in the HNSCC
TME, and a successful anti-PD1 or anti-CTLA4 treatment
induces an enhanced differentiation of T cells to more
activated/differentiated states.
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whole exome sequencing of the two cell lines identiAvailability of data and materials
fied 2452 overlapping variants out of 2649 total variants
The processed data from this study are at NCBI GEO
detected from either cell line (figure 1F). Via NetMHC
(GSE153383), which include bulk RNA-
seq, WES,
pan V.4.0 prediction coupled with RNA-seq data, out of
scRNA-
seq, and scTCR-
seq, The raw sequencing data
are
at
https://www.ncbi.nlm.nih.gov/bioproject/? 371 expressed neoantigens in MOC1, only seven were
predicted as MOC1-specific (online supplemental data
term=PRJNA641208. Both are available to the scientific
1D,E), and only one was in a gene (E130112L23Rik)
community. CyTOF data and custom code used in this
with higher expression in MOC1 than MOC1esc1
work are available on reasonable request. MOC cell lines
(online supplemental data 1D,E).28 These data, together
have been deposited with Kerafast.
with the tumor re-challenge experiments, suggest that
MOC1 and MOC1esc1 still share the vast majority of
RESULTS
their neoantigens. Therefore, the MOC1/MOC1esc1
MOC1 tumors display treatment-induced resistance to antipair represents a novel isogenic model, ideal for invesPD1 therapy
tigating HNSCC responsiveness and resistance to anti-
MOC1 is a syngeneic C57BL/6 background cell line
PD1 and anti-CTLA4.
model which was derived from a carcinogen-induced
oral cavity squamous cell carcinoma. A majority of
High infiltration of regulatory T cells and M2-like
MOC1 tumors show complete response to anti-
PD1
macrophages and MOC1esc1 anti-PD1 resistance
treatment, although 20% of mice reproducibly display
To understand the mechanisms underlying the
an escape phenotype (n=4–5 mice, from two indepenMOC1esc1 resistance phenotype, we performed bulk
dent experiments, figure 1A, online supplemental data
RNA-seq analysis using both in vitro cultured cell lines
1A). In addition, MOC1 tumors are sensitive to anti- and from tumors grown in vivo. At the transcriptomic
CTLA4 treatment with no evident escape phenotype
level, in vitro cultured MOC1esc1 exhibited signifi(online supplemental data 1B). To dissect the mechcant upregulated expression of Myc and E2f target
anisms of MOC1 resistance to anti-PD1, we generated
genes (figure 2A), which have been described as part
a cell line (MOC1esc1) from a single escape tumor.
of an immune resistance program in human melaWhen MOC1esc1 cells were retransplanted into naïve
noma and pancreatic adenocarcinoma.6 7 In addition,
wild-type mice and treated with anti-PD1, these tumors
MOC1esc1 had decreased interferon-
alpha (IFNα),
displayed complete resistance (figure 1B). Thus, MOC1
interferon-gamma (IFNγ), and inflammatory response
and MOC1esc1 represent an isogenic model pair with
gene signatures (figure 2A), in line with the reduced
parental sensitive and anti-PD1 resistant phenotypes,
IFNγ-induced cell surface expression of Class I and
respectively (figure 1B). Interestingly, MOC1esc1
PD-L1 on MOC1esc1 compared with MOC1 (figure 1E).
CTLA4 treatment
tumors remained sensitive to anti-
Congruent with in vitro RNA-seq, analysis of in vivo
(online supplemental data 1B, figure 1B).
bulk tumors revealed that the expression of Myc and
The tumor growth rate of MOC1esc1 was faster
E2f target genes were higher in MOC1esc1 than MOC1
than MOC1 in both immunocompromised NOD.Cg-
tumors (figure 2B). The in vitro and in vivo RNA-seq
PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice and immunocompedata suggest that a cancer cell-intrinsic immune resistent C57BL/6 mice, consistent with an overall more
tance program, including Myc and E2f targets and
aggressive phenotype (figure 1C). As immune editing
several downregulated immune-
related gene sets,
induced by anti-PD1 treatment might result in attenincluding inflammatory responses, allograft rejection,
uation of antigen presentation or antigen-
loss,27 we
and IFNγ response acquired by MOC1esc1 might faciliasked whether MOC1esc1 represented such a variant
tate tumor immune evasion (figure 2B).
of MOC1. We evaluated basal and IFNγ stimulated cell
To further investigate the MOC1esc1 cell-
intrinsic
surface Class I H2-Kb and PD-L1 levels of MOC1 and
effect on the immune TME, we employed CyTOF to
MOC1esc1 cells. While MOC1 and MOC1esc1 cells
comprehensively profile TME in untreated MOC1 and
had similar basal levels of H2-Kb and PD-L1, MOC1esc1
MOC1esc1 tumors (n=4 in each group, figure 2C–E,
showed significantly lower cell surface expression levels
online supplemental data 2). Single cell suspension
of both H2-Kb and PD-L1 in response to IFNγ stimulasamples of individual MOC1 or MOC1esc1 tumors were
tion (figure 1D, online supplemental data 1C), indibarcoded then pooled together for antibody panel
cating a reduced IFNγ response in MOC1esc1 cells.
staining. Gating on CD45 +cells, we observed that
We next asked whether MOC1esc1 shared the same
while CD8 +T cell levels were similar between the two
major antigens as MOC1. We performed MOC1 tumor
models (figure 2C–E), MOC1esc1 tumors had signifirechallenge experiments in mice cured of MOC1esc1
cantly higher infiltration of regulatory T cells (Tregs)
via anti-CTLA4 and surgical resection of any residual
and conventional CD4 +T cells compared with MOC1
tumors (figure 1E). MOC1esc1-
experienced mice
tumors. MOC1esc1 tumors were also highly infiluniformly rejected MOC1 tumor re-challenge, further
trated by CD206 +M2 like TAMs. The percentages of
indicating that the major antigens of MOC1 were still
tumor-
associated neutrophils in MOC1esc1 tumors
maintained in MOC1esc1 (figure 1E). In addition,
were lower than MOC1. The correlation between high

Open access

tumor infiltration levels of Tegs and TAM and HNSCC
progression has been reported previously,29–31 consistent with an immunosuppressive role of Tregs and
TAMs in endogenous anticancer immunity of HNSCC
patients. Similarly, the high infiltration levels of Tregs
and TAMs may also contribute to an immunosuppressive TME of MOC1esc1. Together, these data suggest
4

that, compared with MOC1, MOC1esc1 tumors have
higher levels of immunosuppressive M2-like TAMs and
Tregs in the TME.
We next examined the TME of MOC1esc1 tumors
on anti-PD1 or anti-CTLA4 treatment to identify the
suppressive immune components involved in anti-PD1
resistance (figure 3A–C, online supplemental data 3). As
Zhou L, et al. J Immunother Cancer 2022;10:e004034. doi:10.1136/jitc-2021-004034
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Figure 1 A carcinogen-induced HNSCC model, MOC1, displays adaptive resistance to anti-PD1. (A) MOC1 anti-PD1
sensitivity and escape tumor growth. MOC1 bearing C57BL/6 mice were treated with anti-PD1 or isotype control on days 3, 6
and 9 (n=4–5 each group). This experiment was repeated two times. The indicated escape tumor was harvested and cultured
to generate polyclonal MOC1esc1. (B) C57BL/6 mice bearing MOC1esc1 tumors were resistant to anti-PD1, but sensitive
to anti-CTLA4 therapy (n=4 per group). (C) Growth curves of MOC1 and MOC1esc1 tumors in immunodeficient NSG or
immunocompetent C57BL/6 mice (n=4 per group). (D) Cell surface protein levels of H2-Kb and PD-L1 on MOC1 and MOC1esc1
treated with indicated IFNγ concentrations for 48 hours were measured by flow cytometry (**p<0.01, ***p<0.001). Significance
was calculated by unpaired Student’s t-test. Data are shown as Mean±SD, n=3 per group. (E) Tumor rechallenge studies.
C57BL/6 mice implanted with MOC1esc1 tumors were cured of tumor with anti-CTLA4 (50%) and surgical resection as needed
(50%) of any residual or growing tumors. After 6 weeks of rest, tumor free mice were rechallenged with parental MOC1 or
MOC1esc1 lines and monitored for tumor growth. Age-matched naive C57BL/6 mice were implanted with MOC1 or MOC1esc1
as control groups. n=6–8 per group. (F) Clonality plots comparing variant allele frequency (VAF) of single nucleotide variants
(SNVs) in MOC1 and MOC1esc1 lines, with red dots representing predicted neoantigens. Venn diagram showing the numbers of
SNVs in MOC1 and MOC1esc1 lines. HNSCC, head and neck squamous cell carcinoma; MOC1, murine oral carcinoma.

Open access

expected, anti-CTLA4 (clone 9D9) selectively reduced
the frequency of Tregs. Although both anti-PD1 and
anti-CTLA4 significantly increased total CD8 +T cells
and granzyme B producing CD8 +T cells compared with
control treatment (figure 3B–D), anti-CTLA4 treatment
resulted in a larger increase of CD8 +T cells in the tumor
than anti-PD1 (figure 3B–D). In the anti-PD1 treated
resistant tumors, the M1/M2 ratio was significantly
lower than in control or anti-CTLA4 treated responding
Zhou L, et al. J Immunother Cancer 2022;10:e004034. doi:10.1136/jitc-2021-004034

tumors, indicating an immunosuppressive TAM phenotype in the resistant tumors (figure 3B–D). To examine
the contribution of TAMs, we used anti-
CSF1R to
manipulate myeloid cells. In the MOC1esc1 tumor-
bearing mice, the combination of anti-PD1 and anti-
CSF1R therapy suppressed tumor progression (online
supplemental data 4A,B). However, specific conclusions
on myeloid cell contribution are limited as anti-CSF1R
may have a wider impact. We, therefore, focused on the
5
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Figure 2 MOC1esc1 tumors are highly infiltrated by Tregs and M2-like TAMs. (A) In vitro RNA-seq analysis revealed distinct
transcriptomic changes between MOC1 and MOC1esc1 lines. Enriched hallmark gene sets are shown by heatmap of gene
mRNA expression levels. All gene sets were enriched with FDR<0.001. (B) RNA-seq analysis of MOC1 and MOC1esc1 bulk
tumor samples from day 14 after implantation (N=3 per group). Hallmark gene sets enriched for upregulated and downregulated
mRNAs were visualized using mRNA expression value heatmaps. All gene sets were enriched with FDR<0.001 between
MOC1 and MOC1esc1 tumors ranked by normalized enrichment score. (C) Immune profiling of MOC1 and MOC1esc1
TME in treatment naïve tumors using mass cytometry. Tumors were harvested on day 14 after implantation and stained
with a 37-marker antibody panel. Density viSNE plots were used to visualize an even number of CD45 +cells from MOC1
or MOC1esc1 tumors. (D) ViSNE plots of tumor infiltrating CD45 +cells overlaid with the expression of selected markers.
(E) Frequency within CD45 +cells of major immune cell compartments in treatment naïve MOC1 and MOC1esc1 TME. The
percentage of CD45 +live cells in each condition is: MOC1:88.3±5.8%, MOC1esc1: 77±5.8%. (*P<0.05, **p<0.01, ***p<0.001.
Significance was calculated by unpaired Student’s t-test. Data are shown as mean±SEM, N=4 per group). DC, dendritic
cell; FDR, false discovery rates; MOC1, murine oral carcinoma; ViSNE: visual stochastic network embedding; TAMs, tumor-
associated macrophage.
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Treg contribution and found that treatment with anti-
CD25 plus anti-PD1 resulted in complete rejection of
MOC1esc1 tumors and these mice were protected from
rechallenge with MOC1esc1 (online supplemental data
4C). Therefore, Tregs contributed to MOC1esc1 anti-
PD1 resistance.
Single-cell RNA-seq analysis defines distinct subsets of CD8
TILs
We next applied single-cell RNA sequencing (scRNA-seq)
coupled with single-
cell TCR sequencing (TCR-
seq)
to further investigate MOC1esc1 intrinsic resistance.
MOC1esc1 tumors treated with isotype control, anti-PD1,
6

or anti-
CTLA4 were harvested and viable CD45 +cells
were isolated and analyzed by scRNA-seq and TCR-seq
(figure 4A, online supplemental data 5A and 6A). Unsupervised clustering identified 16 unique clusters, which
were annotated by known marker genes of specific
immune cell populations (figure 4A, online supplemental
data 5B,C).
Focusing on single-cell transcriptomic profiles of T cells
in the MOC1esc1 tumors, we identified several subsets
of CD3 +T cells. We annotated two CD4 +T cell subsets
including Tregs (Foxp3+) and conventional CD4 +T cells
(CD4conv, Foxp3-) (figure 4B). Next, we annotated four
Zhou L, et al. J Immunother Cancer 2022;10:e004034. doi:10.1136/jitc-2021-004034
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Figure 3 Tregs and M2-like TAMs contribute to MOC1esc1 anti-PD1 resistance. (A) Schematic of MOC1esc1 tumor bearing
mice treatment and analysis. MOC1esc1-bearing mice were treated with isotype control, anti-PD1, or anti-CTLA4 monoclonal
antibodies on days 3, 6, 9 after tumor implantation. Tumors were harvested on day 12 and subsequently analyzed by a
37-marker panel using CyTOF. (B) ViSNE plots of tumor infiltrating CD45 +cells overlaid with the expression of selected markers.
T cells: CD3+, CD8 +T cells: CD3 +CD8+, GzmB +CD8+T cells: CD3 +CD8+GzmB+, Tregs: CD3 +CD4+Foxp3+, CD4conv:
CD3 +CD4+Foxp3-, B cells: CD19+, NK cells: NK1.1+, M2-like macrophage: CD11b+F4/80+Ly6C-Ly6G-CD206+, M1-like
macrophage: CD11b+F4/80+Ly6C-Ly6G-CD206-, Neutrophils: CD11c-CD11b+Ly6G+, Monocytes: CD11c-CD11b+Ly6G-
Ly6C+. (C) Profiling of MOC1esc1 TME under indicated treatments gated on CD45 +cells. Density viSNE plots were used
to visualize an even number of CD45 +cells from three indicated treatment groups. Selected major immune populations
were labeled. (D) Frequency of major immune compartments in MOC1esc1 tumors under different treatment conditions. The
percentage of CD45 +live cells in each condition is: isotype control: 88.2±3.1%, anti-PD1:87.4±1.3%, anti-CTLA4:89.9±2%.
(*P<0.05, **p<0.01, ***p<0.001. Significance was calculated by one-way ANOVA. Data are shown as mean±SEM, n=5 mice
per group). ANOVA, analysis of variance; MOC1, murine oral carcinoma; TAMs, tumor-associated macrophages; TME, tumor
microenvironment.
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major CD8 +T cell subsets as Tcf7 +Pd1−, Tcf7 +Pd1+,
Tcf7-Pd1+, and proliferative Mki67 +using specific marker
genes of T cell naïve/memory, activation, effector, and
proliferation. The Tcf7 +Pd1− subset showed the highest
expression of naïve/memory genes (such as Tcf7,
Il7r, and Sell), with very low expression of activation/
Zhou L, et al. J Immunother Cancer 2022;10:e004034. doi:10.1136/jitc-2021-004034

effector marker genes (figure 4C). The Tcf7-Pd1+subset
coexpressed high levels of inhibitory receptors, as well
as high effector molecule levels, indicating a differentiated effector T cell phenotype (Teff) (figure 4C).
The Tcf7 +Pd1+subset showed intermediate levels of
naïve/memory, effector, and coinhibitory molecules in
7
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Figure 4 Single-cell RNA-seq analysis defines distinct subsets of CD8 TILs. (A) UMAP of scRNA-seq results of total tumor
infiltrating CD45 +cells pooled from different treatment groups. Tumor infiltrating CD45 +cells from 5 mice in the same treatment
group were pooled and subjected to single cell sequencing. (B) UMAP of total T cells in MOC1esc1 tumors colored by indicated
major subsets. T cells from all three conditions were pooled for clustering analysis. (C) Heatmap illustrating the relative gene
expression levels of genes in major T cell subsets in MOC1esc1 tumors. (D) Tcf7 +Pd1−, Tcf7 +Pd1+, and Tcf7-Pd1+CD8+T
cells in MOC1esc1 tumors were detected by flow cytometry. Dot plot was pre-gated on live CD8 +T cells. Percentages of
CD8 +subsets in MOC1esc1 tumors at indicated treatment condition are shown. MOC1esc1 tumors treated with isotype
control, anti-PD1, or anti-CTLA4 were harvested at day 12 postinoculation and analyzed by flow cytometry for CD8 +T cell
subset distribution (*p<0.05, ***p<0.001). Significance was calculated by one-way ANOVA. Data are shown as mean±SEM,
n=5 mice per group.) (E) Pseudo-bulk differential expression analysis was performed in total CD8 +T cells between responder
(anti-CTLA4) and control MOC1esc1 tumors. Colors of dots represent the anti-CTLA4 treated MOC1esc1 infiltrating CD8 +T cell
upregulated genes (red) and downregulated genes (blue) compared with control. The statistical significance (log10 FDR) was
plotted against the log2 fold-change of gene expression levels. ANOVA, analysis of variance; FDR, false discovery rates; MOC1,
murine oral carcinoma; TILs, tumor infiltrating lymphocytes; UMAP, uniform manifold approximation and projection.
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Subsets of CD8+ TILs differentially respond to ICB
Having identified of CD8 +TIL subset changes with
ICB, we next performed pseudotime analysis to place
cells along the expected differentiation trajectories in
order to start understanding the transcriptomic profiles
of individual T cell subsets under different response/
resistant conditions. Cells in different conditions were
assumed to be from a diffusion process and could be
inferred from the data-related diffusion operator.34 All
CD8 +T cells in distinct subsets of individual conditions
were ordered along the differentiation trajectory based
on changes in their transcriptomes. Within the Tcf7 +Pd1
cell subset, anti-CTLA4 treatment induced a significantly
more differentiated T cell state than control or anti-
PD1 treatment (figure 5A). To definitively establish the
clonal trajectory of the tumor infiltrating T cells, we integrated TCR-seq with scRNA-seq data (figure 5B,C, online
supplemental data 6A–C). Both anti-
CTLA4 and anti-
PD1 treated tumors had more clonal T cells, which was
defined by more than two T cells sharing the same TCRα
and βchain, than control tumors (online supplemental
data 6B). A TCR clone size heatmap was projected onto
the UMAP plots of T cells to delineate the distribution of
clonally expanded T cells within the major T cell subsets
(figure 5B). In control tumors, Tprogenitor (Tcf7 +Pd1+)
and Teff (Tcf7-Pd1+) had comparable numbers of clonal
expanded T cells. In anti-PD1 treated resistant tumors,
Teff were preferentially expanded, while Tprogenitor did
not show higher clonal expansion compared with control
(figure 5B). In anti-CTLA4 treated responding tumors,
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both Teff and Tprogenitor showed dramatic clonal expansion (figure 5B). These data are consistent with several
reports identifying Tcf7 +Pd1+Tprogenitor as a critical T
cell subset in anti-PD1 response with self-renewal capacity
to differentiate to Teff.21 35–37 Moreover, in resistant and
control tumors, clonal CD8 +T cells were primarily distributed in the Pd1 +subsets but not the Tcf7 +Pd1− subset. In
contrast, clonal T cells were distributed in all 4 subsets of
CD8 +T cells, even in the Tcf7 +Pd1− population, in the
anti-CTLA4 condition (figure 5B, online supplemental
data 6B). We also observed individual T cell clonotypes
spanning Tcf7 +Pd1−, Tcf7 +Pd1+, and Tcf7-Pd1+subsets
only in anti-CTLA4 treated responding tumors (online
supplemental data 6C), indicating higher T cell clonal
dynamics in responding tumors. Together, in addition
to the clonal expansion of Tprogenitor in responding
tumors, we identified distinct clonal dynamics of naïve/
memory-like Tcf7 +Pd1− subset in anti PD-1 resistant vs
anti-
CTLA4 responding MOC1esc1 tumors. Our data
illustrate the interplay of global CD8 +TIL population
architecture and clonal dynamics in anti-PD1 resistant
and anti-CTLA4 responses in this HNSCC model.
Lineage transitions between CD8+ TIL subsets on ICB
treatment
To investigate whether T cell dynamics on anti-CTLA4
treatment were related to lineage transitions between
individual CD8 +T cell major subsets, we evaluated
shared TCR clones with identical TCR CDR3 amino
acid sequences from the MOC1esc1 model. We assessed
the shared TCR fractions between every pair of CD8 T
cell subsets, where 0 indicates no overlap/transition
and one indicates identical match of all clonotypes
(figure 5C). These analyses showed that in the control
and resistant conditions, the Tcf7 +Pd1− subset have
negligible levels of overlapping TCR clonotype fractions
with Pd1 +subsets. However, in anti-CTLA4 responding
tumors, the Tcf7 +Pd1− subset shared TCR clonotypes
with all the other subsets (Tcf7 +Pd1+, Mki67+, and Tcf7-
Pd1+) totaling 37% (14%+7%+16%) clonotype overlap
(figure 5C, first row). In addition, the transitions between
Tcf7 +Pd1+or Mki67 +and Tcf7-Pd1+were also dramatically increased to 75% (36%+39%), compared with 15%
(9%+6%) in control and 19% (5%+14%) in anti-PD1
resistant conditions (figure 5C, last column). These analyses suggest that an enhanced lineage transition between
naïve/memory-like Tcf7 +Pd1−, progenitor Tcf7 +Pd1+,
and differentiated effector Tcf7-
Pd1+subsets might be
involved in a productive T cell antitumor response in
MOC1esc1. Therefore, an anti-
PD1 or anti-
CTLA-
4-
induced antitumor T cell response might involve the
differentiation process of naïve/memory-like Tcf7 +Pd1
to Pd1 +subsets and progenitor Tcf7 +Pd1+to the differentiated effector Tcf7-Pd1+subset.
To further explore the role of tumor infiltrating Tregs in
CD8 +T cell-mediated antitumor response, we tested the
effect of Treg depletion on the distribution of tumor infiltrating CD8 +T cell subsets using flow cytometry (online
Zhou L, et al. J Immunother Cancer 2022;10:e004034. doi:10.1136/jitc-2021-004034
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between Tnaïve/memory and Teff, indicating a progenitor/precursor T cell phenotype (Tprogenitor)21 32 33
(figure 4C). These major subsets of CD8 +T cells exhibited a clear spectrum ranging from naive/memory-like to
differentiated effector phenotypes. Using flow cytometry,
we further confirmed the presence of these CD8 +TIL
subsets in MOC1esc1 tumors (figure 4D, online supplemental data 5D). We then assayed tumor infiltrating
CD8 +T cells for the proportions of the TCF7 +PD-1-/
TCF7 +PD-1+/TCF7-PD-1+CD8 T cells in the MOC1esc1
tumor under different treatment conditions (figure 4D).
The results showed that anti-
CTLA4 dramatically
decreased the percentage of TCF7 +PD-
1- subset and
increased the percentage of TCF7-PD-1+subset in CD8 +T
cells. In addition, anti-CTLA4 also slightly lowered the
proportion of TCF7 +PD-1+CD8+T cells compared with
control and anti-PD1 treatment. These data suggested
that anti-CTLA4 treatment promoted the expansion of
effector CD8 +T cells in MOC1esc1 model.
To investigate the overall impact of successful anti-
CTLA4 treatment on CD8 +TILs, we performed a
pseudobulk differential expression analysis of CD8 +T
cells from anti-CTLA4 and isotype control treated tumors.
We found that a significant decrease of naïve/memory
genes (Tcf7, Ccr7, and Lef1) and an increase of T cell
activation genes (Gzmb, Gzma, and Lag3) were associated
with a productive anti-tumor T cell response (figure 4E).
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supplemental data 7). Tumor-
bearing mice received
isotype control, anti-PD1 single therapy, anti-CD25 single
therapy, or the combination of anti-PD1 and anti-CD25.
FACS analysis of CD8 +T cell subsets showed that the
combination of the anti-PD1 and anti-CD25 resulted in
a dramatic decrease of PD1−TCF7+naïve/memory like
subset proportion in total CD8 +T cells compared with
isotype control or either single treatment groups. The
Zhou L, et al. J Immunother Cancer 2022;10:e004034. doi:10.1136/jitc-2021-004034

proportion of PD1 +TCF7+progenitor CD8+T cells subset
was not significantly affected by these treatments. Treatment with anti-
PD1 plus anti-
CD25 also dramatically
increased the PD1 +TCF7- differentiated effector subset
proportion compared with isotype control or either single
treatment groups (online supplemental data 7B). In addition, the combination of anti-CD25 and anti-PD1 elevated
the total immune infiltration and CD8 +T cell infiltration
9
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Figure 5 Subsets of CD8 +TILs differentially respond to ICB. (A) Diffusion pseudotime of indicated CD8 +T cell major subsets
in distinct treatment conditions. (*P<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Significance was calculated by one-way ANOVA.)
(B) Heatmap of TCR clone size. Cells were colored by TCR clone size on a log2 scale in the UMAP of T cells in indicated
conditions of MOC1esc1 tumors. (C) Shared fraction analysis heatmaps of TCR clonotypes between primary and secondary
phenotypes in indicated conditions of MOC1esc1 tumors. ANOVA, analysis of variance; ICB, immune checkpoint blockade;
MOC1, murine oral carcinoma; TILs, tumor infiltrating lymphocytes; UMAP, uniform manifold approximation and projection.
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Transcriptomic and clonal dynamics of major TIL subsets in
MOC22 tumors with anti-PD1 treatment
To generalize the observation of T cell differentiation
in immunotherapy responses in an additional HNSCC
model, we analyzed MOC22, a distinct carcinogen-
induced murine HNSCC model with complete response
PD1 treatment.23 38 We conducted scRNA-
seq
to anti-
and TCR-
seq on the MOC22 tumor from the control
and anti-PD1 group, respectively (online supplemental
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data 9A,B). Similarly, unsupervised clustering identified
four major subsets of CD8 +T cells with distinct phenotypes: Tcf7 +Pd1−, Tcf7 +Pd1+, Tcf7-Pd1+, and Mki67+
(figure 6A–D). The Tcf7-
Pd1+subset also coexpressed
effector/coinhibitory genes, such as Ifnγ, Tim3, and Lag3
(figure 6C,D). We were surprised to see a large number
of CD8 +T cells showing a naïve/memory-like Tcf7 +Pd1−
phenotype with control treatment (figure 6E). Interestingly, on anti-PD1 treatment, CD8 +T cells dramatically
shifted toward the Tcf7-
Pd1+phenotype (figure 6E).
Consistent with the results of MOC1esc1 anti-
CTLA4
responsive condition (figure 4E), differential expression
analysis of total CD8 +T cells revealed that anti-PD1 treatment also increased the expression levels of genes associated with T cell activation (Lag3, Pdcd1, Gzmb) and
decreased the expression levels of genes in T cell naïve/
memory phenotype (Tcf7, Ccr7, Lef1) in MOC22 tumors
(figure 6F).
Pseudotime analysis revealed that Tcf7 +Pd1 cells in
anti-
PD1 treated tumors were at a significantly more
differentiated state towards the activated/effector phenotype compared with control tumors (figure 7A). By
projecting a TCR heatmap onto the UMAP plots of T cells
in MOC22 tumors, we found that in both control and anti-
PD1 groups, T cells with the highest clone numbers were
largely within Tcf7-Pd1+subset, while Tcf7 +Pd1 cells were
in smaller clones overall (figure 7B). T cell lineage transition analysis showed that the shared fractions of clonotypes between Tcf7 +Pd1 and Tcf7-Pd1+or Mki67 +was
remarkably increased from 0 in control to 30% in anti-
PD1 treated responding tumors (figure 7C). These data
confirmed that a productive antitumor response involves
a CD8 +T cell lineage transition/differentiation from
Tnaïve/memory Tcf7 +Pd1 to Teff Tcf7-Pd1+subset in the
MOC22 model.
DISCUSSION
Overcoming ICB resistance to benefit a greater proportion of patients is dependent on a better understanding
of the cellular mechanisms in the TME on ICB treatment
in both sensitive and resistant conditions. In this study,
we generated a novel isogenic paired anti-PD1 parental
sensitive/resistant model system, MOC1/MOC1esc1, that
showed surprizing retention of anti-CTLA4 response .
Transcriptomic analysis of MOC1esc1 identified components of conserved ICB resistance pathways previously
defined in human melanoma and murine pancreatic
cancer models.6 7 Mass cytometry-
based characterization of MOC1 and MOC1esc1 TME highlighted a role
for Tregs and M2-
like TAM in anti-
PD1 resistance of
MOC1esc1. ScRNA-seq and coupled TCR-seq analysis of
TILs in independent HNSCC murine models identified a
spectrum of CD8 +TILs major subsets. We demonstrated
that a successful anti-PD1 or anti-CTLA4 therapy induced
the differentiation of TILs from Tcf7 +Pd1− naïve/
memory-
like to Pd1 +activated/differentiated states in
these murine HNSCC models. To our knowledge, our
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levels in MOC1esc1 tumors (online supplemental data
7C). Anti-
CD25 single treatment did not significantly
change CD8 +T cell subset distribution. Therefore, the
combination of anti-PD1 and anti-CD25 antibody resulted
in altered distribution of individual CD8 +T cell subsets,
where the naïve/memory like T cells were reduced and
differentiated effector cells were increased. Together,
these data suggested a critical role of Tregs in modulating
CD8 +T cell subset distribution.
We next extended this scRNA-seq analysis to the MOC1
parental line (online supplemental data 8A). Similar to
MOC1esc1, we observed the same major T cell subpopulations, including Foxp3 +Tregs, CD4conv, Mki67 +and
CD8+T cells. Within the CD8 +T cells, we identified
the same spectrum of CD8 +TIL major subsets in the
parental MOC1 model: naive/memory-like TCF7 +PD1−,
Tprogenitor TCF7 +PD1+, Teff TCF7-PD1+and MKi67+
(online supplemental data 8B–D). MOC1 tumors are
responsive to both anti-PD1 and anti-CTLA4 consistent
with either treatment condition demonstrating a productive T cell antitumor response. TCR clone size heatmaps
showed that clonal CD8 +T cells distributed mainly in the
Tprogenitor and Teff subsets in the control condition.
Anti-PD1 or anti-CTLA4 treatment dramatically increased
the frequencies of clonal expanded T cells compared
with control, which were also mainly in Tprogenitor and
Teff subpopulations (online supplemental data 8E) and
consistent with the potential killing function of terminally
differentiated T cells.
Distinct from MOC1esc1 results, the naïve/memory-
like TCF7 +PD1 cells did not show significant clonal
expansion in either anti-PD1 or anti-CTLA4 responding
condition (online supplemental data 8E). Shared TCR
fractions between naïve/memory-
like TCF7 +PD1 and
other CD8 +subsets were very low (less than 5%) still
indicating the differentiation and expansion of more
clonotypes in naïve/memory-
like cluster to activated/
exhausted PD1 +phenotypes (online supplemental data
8F). In addition, we observed a dramatic increase of
shared TCR fractions between TCF7 +PD1+Tprogenitor
and MKi67 +with Teff in anti-PD1 and anti-CTLA4 treated
tumors compared with control condition, respectively
(5% in control vs 32% in anti-PD1, 37% in anti-CTLA4)
(online supplemental data 8F). In summary, these results
are consistent with the differentiation of both TCF7 +PD1
and TCF7 +PD1+to more activated/exhausted phenotypes being involved in a productive T cell antitumor
response induced by ICB treatment.

Open access

work is the first to highlight these dynamics for anti-
CTLA4 therapy. Importantly, by defining critical T cell
states induced by ICB in these models, this work sets the
stage for ongoing and future mechanistic studies to delineate influence of T cell state on immunological outcomes.
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The establishment of MOC1esc1 line is likely the result
of clonal selection from a polyclonal MOC1 parental line
due to the immune selection pressure induced by anti-
PD1 treatment. Compared with the acquired resistance
to targeted therapies, the MOC1 tumor developed resistance within a relatively short period of time (about 1
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Figure 6 Major TIL subsets and the transcriptomic dynamics in MOC22 tumors with anti-PD1 treatment. A total of 5, 548
T cells were sequenced in MOC22 tumors treated with isotype control or anti-PD1. T cells from five mice in each treatment
group were pooled and subjected to single cell sequencing. (A) UMAP of T cells in MOC22 tumors colored by individual
clusters. (B) Violin plots showing expression of selected immune cell marker genes across clusters. The y axis represents the
normalized gene expression levels. (C) UMAP of total T cells in MOC22 tumors colored by indicated major subsets. T cells from
both conditions were pooled for clustering analysis. (D) Heatmap illustrating the relative gene expression levels of genes in
major T cell subsets in MOC22 tumors. (E) UMAP of T cells in MOC22 tumors colored by treatment conditions. (F) Pseudobulk
differential expression analysis was performed in total CD8 +T cells between anti-PD1 and isotype control treated MOC22
tumors. The results were presented by a color-coded volcano plot. The statistical significance (log10 FDR) was plotted against
the log2 fold-change of gene expression levels. Each dot represents one gene, which is color coded by the most highly
enriched genes. FDR, false discovery rates; MOC, murine oral carcinoma; TIL, tumor infiltrating lymphocytes.
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month). Importantly, as retransplantation of the escape
line resulted in complete resistance to anti-PD1 therapy,
the resistance is a ‘fixed’ phenotype and consistent with
a cancer cell intrinsic mechanism. Although speculative,
we think that this is likely due to a global, potentially
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epigenetically regulated program. Consistent with this,
we have previously identified Ezh2 as a regulator of
cancer cell antigen presentation machinery in MOC
models by modulating H3K27me3 modification on the
beta-2-microglobulin promotor.39 In line with this, EZH2
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Figure 7 TCR-based lineage tracing showing CD8 +TILs differentiation in MOC22 tumors with anti-PD1 treatment. (A) Diffusion
pseudotime of indicated CD8 +T cell subsets in different treatment conditions. ****p<0.0001. Significance was calculated
by two-tailed Student’s t-test.) (B) Heatmap of TCR clone size in MOC22 tumors. Cells were colored by TCR clone size on a
log2 scale in the UMAP of T cells in indicated conditions. (C) Shared fraction analysis heatmaps of TCR clonotypes between
primary and secondary phenotypes in indicated conditions of MOC22. MOC, murine oral carcinoma; TILs, tumor infiltrating
lymphocytes.
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lung cancer (NSCLC), an EMT score has been proposed
as a predictive biomarker for ICB therapy based on an
strong association between EMT status and immune
checkpoint molecules.47 Thus, the relative contribution
of the EMT signature to the MOC1esc1 immunosuppression is unclear with the ultimate tumor immune microenvironment impact resulting from an integration of all its
distinct associated pathways.
A second limitation is that we were not able to fully interrogate the contribution of M2 macrophages to anti-
PD1
resistance. Our use of anti-CSF1R is not M2-like macrophage
specific, as CSF1R is expressed by multiple immune cell
populations in the TME including dendritic cells, neutrophils, and MDSCs. Therefore, the effect of anti-CSF1R may
be due to depletion of a broad population of myeloid cells.
Indeed, the therapeutic effect of the combination of anti-
CSF1R and anti-PD1 is modest in the MOC1esc1 model. Also
given the fact that we only observed the significant effect of
anti-CSF1R at a high treatment dose, targeting TAM using
anti-CSF1R in MOC1esc1 tumors may not be an effective
therapeutic approach.
This study focused on demonstrating the cellular mechanism of anti-PD1 and anti-CTLA4 treatment sensitivity and
resistance in HPV-HNSCC, which has suboptimal outcomes
in the locally advanced or recurrent/metastatic setting.
As the differentiation from Tprogenitor to Teff has been
shown in SIINFEKL expressing B16 melanoma and chronic
LCMV,21 48 it is possible that the ICB-induced differentiation
of Tnaïve/memory Tcf7 +Pd1 to Pd1 +subsets in CD8 +T cells
may also be identified as a common feature in other cancer
types. Tcf7 +Pd1+cells have been shown to mediate a proliferative response and generate differentiated effector T cells
on immunotherapy treatment.21 49 The dynamic and expansion of Pd1− CD8 +TILs induced by ICB treatment has also
been demonstrated using the MC38-OVA model by Kurtulus
et al.40 A very recent study of human HPV +HNSCC showed
that HPV antigen-specific PD1 +CD8 TILs comprised three
distinct subsets demonstrated by scRNAseq analysis.50 Moreover, HPV-specific stem-like PD1 +TCF7+TILs were able to
proliferate and differentiate to more effector-like cells on
HPV peptide in vitro stimulation.50 All these studies together
have highlighted a newer understanding on the mechanism
of action of ICB therapy beyond ‘conventional’ thinking
about reversing T cell exhaustion. Our data serves as additional validation of the concept that ICB treatment induces
the differentiation and lineage transition of tumor infiltrating CD8 +T cells, and coupled with emerging single-cell
sequencing data from preclinical studies, will further define
the cellular impact of ICB in the TME.
In summary, our study defined the transcriptomic profiles
and TCR-based lineage dynamics of TILs at single-cell resolution in both ICB sensitive and resistant murine HNSCC
models. TCR-
seq analysis revealed the lineage connections and transitions between the major CD8 +TIL subsets,
suggesting distinct differentiation dynamics of TILs in
responding and resistant tumors. Future studies focusing on
identification of critical transcription factors and/or epigenetic modulators involved in the differentiation process of
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inhibition with anti-PD1 was able to attenuate MOC1esc1
growth demonstrating that epigenetic modulators might
contribute to the anti-PD1 resistance in MOC1esc1.
Progenitor CD8 +T cells (Tcf7 +Pd1+) have been
defined using high affinity antigens with cognate transgenic CD8 +T cells to either SIINFEKL in B16-
OVA,
MC38-OVA or gp33 +in chronic LCMV, respectively.21 22 40
These antigens represent high affinity model systems that
allowed definition of T cell subsets but may not capture
the natural anti-tumor antigen specific responses. In this
study, we aimed to define the transcriptomic landscape of
total TILs at the single-cell level with a particular attention to CD8 +T cells, which not only confirmed the presence of Tprogenitor (Tcf7 +Pd1+) and Teff (Tcf7-Pd1+)
populations, but also highlighted a naïve/memory-like
Tcf7 +Pd1− subset with a potential to differentiate into
Pd1 +phenotype on ICB treatment. The distribution of
CD8 +T cell subsets varies in different models, as the
Tcf7 +Pd1− subset was not identified in CD8 +T cells
specific to SIINFEKL in B16-OVA or gp33 +in chronic
LCMV.21 22 40 Although speculative, one potential explanation could be that low affinity T cells may exhibit distinct
phenotypes compared with high affinity T cells. Previous
studies have identified an important contribution of
low affinity T cells in the immune response.41 42 As key
contributors in antitumor immunity, neoantigen-specific
T cells with different affinities to antigen expressing
tumor cells are enriched in the TME.43 44 Such low affinity
tumor specific T cells express lower levels of inhibitory
receptors, indicating that distinct TCR affinities may lead
to diverse TIL phenotypes.45 A testable hypothesis would
be that the TCR signaling pathway has a regulatory function in the expression of stemness or effector markers in
T cells.
One main limitation of the current study is that the analysis of anti-PD1 resistant tumors was focused on only the
MOC1esc1 transplantable model that was derived from
an anti-PD1 treatment-induced resistant tumor. We identified similar immune cell dynamics of effective ICB therapy
responses in independent HNSCC preclinical models, but
there are clearly additional mechanisms of ICB resistance
beyond what we observed in MOC1esc1. The RNAseq
analysis identified differential expression levels of several
distinct pathways between MOC1 and MOC1esc1 that
when integrated, contribute to the MOC1esc1 immunosuppressive state. When broken down, this composite
immunosuppressive signature includes the Myc and
E2F target pathways in MOC1esc1 that are consistent
with other studies showing immune exclusion, but also
includes decreased epithelial-
mesenchymal transition
(EMT). As EMT has been associated with tumor immunosuppression and immune escape, how this relative difference in EMT between MOC1 and MOC1esc1 impacts on
the overall immunosuppressive state is unclear. Ock et al
reported the association between PD-L1 expression and
EMT features in HNSCC cohorts as well as the poor prognosis of EMT high patients but these findings were in the
absence immunotherapy treatment.46 In non-small-cell
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Supplementary methods

Antibodies:
For in vivo study antibodies, rat IgG2a (2A3, Bioxcell), polyclonal hamster IgG (Bioxcell), rat
IgG1 (TNP6A7, Bioxcell), anti-mouse PD-1 (RMP1-14, Bioxcell), anti-mouse CTLA-4 (9D9,
Leinco Technologies), anti-mouse CD25 (PC-61.5.3, Bioxcell), and anti-mouse CSF1R (AFS98,
Bioxcell) were purchased. For fluorescence conjugated antibodies, Rat IgG2b, (RTK4530,
BioLegend), Mouse IgG2a, (MG2a-53, BioLegend), anti-mouse H2-Kb (AF6-88.5.5.3,
Invitrogen), anti-mouse PD-L1(10F.9G2, BioLegend), anti-mouse CD45 (104, BioLegend), antimouse CD3(145-2C11, BioLegend), anti-mouse CD8a (53-6.7, Biolegend), anti-mouse PD1
(29F.1A12, Biolegend), anti-mouse TCF1/TCF7 (C63D9, Cell signaling), Rabbit IgG (DA1E, Cell
signaling) were used. 7-AAD (BioLegend) and Zombie Aqua Fixable Viability Kit (BioLegend)
were used for cellular viability staining.

Whole Exome sequencing, variant analysis, and neoantigen prediction
Genomic DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen). Library
construction was performed using the Agilent Sure Select Whole Exome Capture and captured
using the Agilent SureSelect XT Mouse All Exon probe sets according to the manufacturer
protocol. Libraries were sequenced on the Illumina HiSeq 4000 platform. Reads were aligned to
the mouse reference genome (mm9) using BWA-MEM version 0.7.10 and duplicates were marked
using SAMBLASTER version 0.1.22 [66]. SNVs and small indels were detected using the
Genome Modeling System [38]. Variants were annotated using Ensembl v67 and neoepitopes were
predicted by NetMHC pan 4.0 [39] using epitopes of length 9 against alleles H2-Kb and H2-Db.
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Putative neoantigens were determined by filtering to those with a mutant epitope binding affinity
of less than 500 nM and a fold-change difference (between mutant and wildtype epitopes) greater
than 1.

Tumor re-challenge
Mice cured of MOC1esc1 (10^6 cells) were generated after anti-CTLA4 treatment coupled with
surgical resection of any residual tumors (50% of mice). Mice were rested for 6 weeks and rechallenged with MOC1 (10^6) or MOC1esc1 (10^6) tumor lines in parallel with age-matched
naïve mice. In re-challenge following anti-CD25 in combination with anti-PD1, all the initially
established MOC1esc1 tumors rejected. After 6 weeks’ rest, cured mice and age-matched controls
were re-challenged with MOC1esc1 (10^6). Tumor growth was monitored 2-3 times per week.

Bulk RNA-seq analysis
Total RNA was extracted using RNeasy Plus Mini kit (QIAGEN) according to manufacturer’s
protocol. Standard mRNA library preparation kit (RS-122-2101, Illumina) was used for library
preparation. Libraries were sequenced on Illumina NextSeq 500 platform. Paired read data was
adapted and quality trimmed using Trimmomatic v0.36 [67]. Trimmed reads were quantified by
pseudoalignment against mm10 using Kallisto v0.46.0 [68]. Differential expression analysis was
performed using DESeq2 [69]. Hallmark gene signature enrichment [70] was calculated from
signed -log10 padj values using GSEA Preranked [71]. The variance stabilizing transformed
expression values of the core enrichment genes from each gene set with FDR < 0.001 were plotted
after gene-wise z-score normalization.

Tumor dissociation and FACS analysis:
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MOC1 and MOC1E1 tumors were harvested on day 12 after tumor inoculation. MOC22 tumors
were harvested on day 17 after tumor inoculation. Fresh mouse tumors were minced and digested
using mouse Tumor Dissociation kit (130-096-730) and gentleMACS Dissociator (130-093-235)
from Miltenyi Biotec according to the manufacturer’s instructions. After incubation for 45 min at
37 C, cells were filtered and blocked using Rat Anti-Mouse CD16/CD32 (2.4G2, BD biosciences).
Cells were first stained with Zombie Aqua in PBS to distinguish live/dead cells, then stained with
surface marker antibodies for 20 mins at 4 C degrees. For TCF7 staining, after surface staining,
the cells were fixed using Foxp3/ transcription factor staining buffer set (00-5523-00, eBioscience)
and blocked with rat serum. The cells then were stained with intracellular antibody for mouse
TCF7. All flow cytometry analyses were performed on a MACSQuant analyzer 10 (Miltenyi) and
analyzed using FlowJo10 (Treestar).

ScRNA-seq data Quality Control, UMAP clustering, and cell cluster annotation
We used several QC metrics to identify low-quality cells based on their expression. The utilized
criteria include library size, number of expressed genes, and proportion of reads mapped to
mitochondria. These criteria were selected with the rationale that cells with small library sizes
are of low quality because the RNA might have been lost during library preparation; cells with
very few expressed genes are likely to be of poor quality as the diverse transcript population has
not been successfully captured; cells with high proportion of mitochondrial-mapped genes are
indicative low quality [67]. Ambient RNAs were ruled out with the restriction of cells having
more than 200 sequenced genes. With the counts assessed and quantified, the generated raw gene
count matrices were combined and subsequently converted to a Seurat object for read counts
normalization, scaling, and clustering. A fraction of cells with high abundance (>5%)
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mitochondrial RNA signature was filtered. We used adaptive threshold by identifying cells that
are outliers for the various QC metrics based on the median absolute deviation (MAD) from the
median value of each metric across all cells. a value is considered to be outlier if more than 2
MADs from the median. To remove doublets, we applied DoubletFinder (V2.0) to identify and
remove doublets. To optimize the DoubletFinder performance, the parameter of pK value was
pre-selected by optimizing the performance of Mean-variance normalized bimodality coefficient.

After quality control and unsupervised cell clustering, Uniform Manifold Approximation and
Projection (UMAP) was performed for visualization, and each resulting cluster was conceptualized
as a cell type. Cell type of each cluster was inferred by marker gene enrichment. For this purpose,
a set of top-ranked canonical markers were derived by differential expression across cell clusters.
With the derived marker genes, we used the LM22 profiled by CIBERSORT team to help cell type
annotation. The cell types were annotated in a combination of automatic annotation and manual
curations. To start, we performed automatic cell-type annotation in a supervised manner, which
requires the pre-existing knowledge of marker genes for each cell type. Given the gene signatures
of each cell type, for each cluster, we calculated the summed logFC (cells in one cluster versus all
other cells, which could be both positive or negative) of marker genes divided by log2 total number
of marker genes as the cell-type scores of the input gene signature; the cell type of gene signature
with the highest score is annotated as the cell-type identity of that cluster. The minimum gene
signature score is set to 0, and if the score of all input signatures is less than 0, the cluster will be
annotated as “others.” The immune LM22 gene signature from CIBERSORT team [68] was used
to annotate the cell types. After the automatic annotation, the annotated cell types were manually
revised with known cell type specific marker genes including: CD3e (T cells), CD8a (CD8+ T
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cells), CD4 (CD4+ T cells), Foxp3 (Tregs), Adgre1 (Macrophages), Arg1 (M2-like macrophages),
Klrb1b (NK cells), S100a9 (Neutrophils), Siglech (plasmacytoid Dendritic cells), Ccl22 (Dendritic
cells), Cd19, Cd79 (B cells), Cpa3 (Mast cells).”
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Supplementary Data 2. TME profiling in treatment naïve MOC1 and MOC1esc1 using mass cytometry.
a, ViSNE (within Cytobank) plots of tumor infiltrating CD45+ cells overlaid with the expression of additional
selected markers of major immune cell subpopulations. Cells were total CD45+ cells pooled from both groups
of MOC1 and MOC1esc1 treatment naïve tumors. b, 36 clusters of phenotypically similar cells were identified
using spanning-tree progression analysis of density-normalized events (SPADE) algorithm. c, Heatmap of the
mean intensities of individual phenotypic markers across the 36 clusters after hierarchical clustering.
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Supplementary Data 3. TME profiling of MOC1esc1 upon isotype control, anti-PD1, or antiCTLA4 treatment using mass cytometry. a, ViSNE plots of tumor infiltrating CD45+ cells overlaid
with the expression of additional selected markers of major immune cell subpopulations. Cells were
total CD45+ cells pooled from MOC1esc1 tumors treated with isotype control, anti-PD1, or antiCTLA4 antibodies b, 30 clusters of phenotypically similar cells were identified using SPADE
algorithm. c, Heatmap of the mean intensities of individual phenotypic markers across the 30 clusters
after hierarchical clustering.
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Supplementary Data 4. In vivo depletion experiments confirmed the contribution of Tregs and M2like macrophages in MOC1esc1 anti-PD1 resistance. a, Combination of anti-PD1 and anti-CSF1R

significantly suppressed MOC1esc1 tumor growth. (*P<0.05, **P<0.01, ***P<0.001. Significance was
calculated by one-way ANOVA. Data are shown as mean SEM, N=4 per group.) b, Anti-CD25
monotherapy suppresses MOC1esc1 tumor progression (green line) and combination of anti-PD1 and antiCD25 leads to complete rejection of tumors (blue line). (*P<0.05, **P<0.01, ***P<0.001. Significance
was calculated by one-way ANOVA. Data are shown as mean SEM, N=4 per group.) c, 6 weeks after
tumor rejection, the previously cured of anti-CD25 and anti-PD1 treatment MOC1esc1 bearing mice were

re-challenged with MOC1esc1. Age matched mice were injected with MOC1esc1 cells as control group.
Tumor growth was monitored. (N=6 per group)
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Supplementary Data 5. ScRNAseq analysis of MOC1esc1 tumor infiltrating CD45+ cells.

MOC1esc1 bearing mice were treated with isotype control, anti-PD1, or anti-CTLA4 on Days
3, 6, 9 post tumor implantations. Tumors were harvested on Day 12. 7AAD-CD45+ cells were
flow sorted and subjected to 10x scRNA-seq and TCR-seq. a, Gating strategy for live CD45+
cells sorting of tumor samples. b, Unsupervised clustering identified 15 clusters of CD45+
cells pooled from 3 treatment groups. c, . Violin plots showing expression of selected immune
cell marker genes across clusters. The y-axis represents the normalized gene expression levels.
d, MOC1esc1 tumors harvested at indicated time points were analyzed by flow cytometry for T
cell subset distribution. Percentages of CD8+ subsets in MOC1esc1 tumors at indicated time
points post-inoculation. (*P<0.05, **P<0.01, ***P<0.001. Significance was calculated by oneway ANOVA. Data are shown as mean SEM, N=4 or 5 mice per group.)
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Supplementary Data 6. Extended data supporting the dynamics between major subsets of T cells in
MOC1esc1 tumors. a, Summary of the number of T cells, the number of T cells with productive TCR, the
percentage of T cells with productive TCR and the number of sequenced tumor infiltrating immune cells in
each of the indicated MOC1esc1 treatment conditions. b, Clonal T cells were colored in indicated treatment
conditions. Clonal T cells were defined as cells expressing TCR represented by two or more cells. c, UMAP
of T cells in anti-CTLA4 treated condition with top 5 frequent clonotypes color coded.
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Supplementary Data 7. The effect of Tregs depletion on CD8+ T cell
composition in MOC1esc1 tumors. MOC1esc1 tumors treated with isotype
control, anti-PD1, anti-CD25, or anti-PD1 in combination with anti-CD25 were
harvested at Day 10 post-inoculation and analyzed by flow cytometry for CD8+ T
cell subset distribution. a, Gating strategy for CD8+ T cell subsets. b, Percentages
of CD8+ T cell subsets in MOC1esc1 tumors at indicated treatment conditions are
shown. c, Percentages of CD45+ cells in live events, CD3+ T cells in CD45+
cells, CD8+ T cells in total CD3+ T cells in MOC1esc1 tumors in indicated
treatment conditions are shown. (*P<0.05, **P<0.01, ***P<0.001. Significance
was calculated by one-way ANOVA. Data are shown as mean SEM, N= 4-10
mice per group.)
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Supplementary Data 8. Dynamics and lineage transitions in MOC1 CD8+ TILs.
A total of 10,001 CD3+ T cells were sequenced in MOC1 tumors treated with isotype
control, anti-PD1, or anti-CTLA4. a, Summary of the number of T cells, the number
of T cells with productive TCR, the percentage of T cells with productive TCR in
each of the indicated MOC1 treatment conditions. UMAP of T cells in MOC1 tumors
colored by indicated major subsets from different treatment condition. b.
Unsupervised clustering identified 12 clusters of T cells pooled from 3 treatment
groups of MOC1 tumors. c. Violin plots showing expression of selected T cell
function associated marker genes across clusters. The y-axis represents the
normalized gene expression levels. d, UMAP of total T cells in MOC1 tumors
colored by indicated major subsets. T cells from all 2 conditions were pooled for

clustering analysis. e, Heatmap of TCR clone size. Cells were colored by TCR clone
size in the UMAP of T cells in indicated conditions. f. Heatmap showing the shared
fractions of TCR between primary and secondary phenotypes in indicated conditions.
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